PPT-Atrial Fibrillation Long-Term Outcomes in Patients With AF

ICH in Asians Causes of Death in Patients With AF 2Year Outcome Data From GARFIELDAF Assessing Risk CHA 2 DS 2 VASc Event Rates Stratified by CHA 2 DS 2 VASc MetaAnalysis of NOACs vs Warfarin. fibrillation: diagnosis and management. د. حسين محمد جمعة . اختصاصي الامراض الباطنة . البورد العربي . كلية طب الموصل . 2010. de la Fibrillation . Auriculaire. en . Pratique. de Ville. Samer. Nasr, M.D.. Mount Lebanon Hospital.. Classification. Lone . atrial. fibrillation:. Younger than 60 years old.. No clinical or echo evidence of cardiopulmonary disease.. Journal Club . October 21,2015. Kathleen McNamara, . PharmD. Stroke Risk Calculation. Which tool do you most typically use to evaluate stroke . risk for patients with a fib? . CHADS2 score. CHADS2-VASc. Amit Kishore. Consultant and Honorary Senior Lecturer . in Stroke Medicine , . SRFT. Amit.Kishore@srft.nhs.uk . January 2017. Cryptogenic strokes. ‘. Brain infarction . that is not attributable to a source of definite . A . CASE SERIES AND REVIEW OF THE LITERATURE . 1. Lily . K. . Fatula. , BS; . 1,2. William . D. Bolton, MD; . 1,2. Barry . R. Davis, MD; . 1,2. James . E. Stephenson, MD; . 1,2. Sharon . Ben-Or, MD. . Mary N. Healy, MS, ARNP-BC. Heart & Vascular Center of Sarasota. OBJECTIVES. Define the difference between paroxysmal and persistent Atrial Fibrillation. State the CVA risk per year of a 68 . yr. Overview . Definition and epidemiology. Symptoms. Tests/Evaluations. Complications. Treatment. Effects on exercise. Medications effect on exercise. Effects of training. Exercise prescription. Definition. A . CASE SERIES AND REVIEW OF THE LITERATURE . 1. Lily . K. . Fatula. , BS; . 1,2. William . D. Bolton, MD; . 1,2. Barry . R. Davis, MD; . 1,2. James . E. Stephenson, MD; . 1,2. Sharon . Ben-Or, MD. . CLINICAL associate professor,. New york . medical college.. Objectives. Introduction & Definitions. Epidemiology and Risk Factors. Classification of Atrial Fibrillation. Evaluation & Diagnostics. . John Windle MD October 18, 2013. Professor and Chief of Cardiology. University of Nebraska Medical Center. “Ha . ha. . ha. , Biff. Guess what? After we go to the drugstore and the post office, . Carlos Calle-Muller, MD. Cardiac Electrophysiology. 734-855-9448. Objectives. To recognize the risks for patients with atrial fibrillation. To familiarize with the management of atrial fibrillation. Atrial fibrillation (AF) is the most common cardiac arrhythmia . Amir Shaikh, MD; David D McManus, . MD,ScM. Assistant Professor,. Department of Medicine. University of Massachusetts Medical School, Worcester, MA, USA. Disclosures. David D McManus, MD, . ScM. has received research funding from: . Wessex. A report for Wessex AHSN ‘Atrial Fibrillation: Detect, Perfect, Protect’ . Programme. Dr . Anastasios. Argyropoulos. Centre for Implementation Science. A.Argyropoulos@soton.ac.uk . Wessex. Freedom . from atrial fibrillation at 12 . months: 63. % of the mitral valve surgery plus ablation group . vs. . 29% of the mitral valve surgery alone group (p < . 0.001). Among . the ablation group, freedom from atrial fibrillation occurred in 61% with PVI vs. 66% with .